Resistance to direct inhibitors is a significant challenge in cancer treatment. Cancer cells can develop mutations that render the inhibitor ineffective. To manage resistance, researchers are developing second- and third-generation inhibitors designed to overcome these mutations. Combination therapies that target multiple pathways simultaneously are also being explored to prevent or delay the onset of resistance.
